StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics r&d expenses

Research and development expenses are spending on new products and technology.

Myriad Genetics's R&D Expenses for the twelve months ending Jun 30, 2026 was $105.80M, down 7.0% year over year. For fiscal 2025 it was $106.80M, down 5.8% from the year before. Over ten years it grew 4.7% a year on average. The highest annual figure on record is $113.40M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$106.80M-5.8%
FY2024Dec 31, 2024$113.40M+27.8%
FY2023Dec 31, 2023$88.70M+3.9%
FY2022Dec 31, 2022$85.40M+10.6%
FY2020Jun 30, 2020$77.20M-10.1%
FY2019Jun 30, 2019$85.90M+21.3%
FY2018Jun 30, 2018$70.80M-4.8%
FY2017Jun 30, 2017$74.40M+5.4%
FY2016Jun 30, 2016$70.60M-6.5%
FY2015Jun 30, 2015$75.50M+11.9%
FY2014Jun 30, 2014$67.50M+25.7%
FY2013Jun 30, 2013$53.70M+25.9%
FY2012Jun 30, 2012$42.65M+53.7%
FY2011Jun 30, 2011$27.75M+26.9%
FY2010Jun 30, 2010$21.87M+22.1%
FY2009Jun 30, 2009$17.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$25.00M-2.3%
Q1 FY2026CQ1 2026Mar 31, 2026$27.10M-1.5%
Q4 FY2025CQ4 2025Dec 31, 2025$25.50M-20.8%
Q3 FY2025CQ3 2025Sep 30, 2025$28.20M-1.1%
Q2 FY2025CQ2 2025Jun 30, 2025$25.60M-5.5%
Q1 FY2025CQ1 2025Mar 31, 2025$27.50M+10.4%
Q4 FY2024CQ4 2024Dec 31, 2024$32.20M+53.3%
Q3 FY2024CQ3 2024Sep 30, 2024$28.50M+18.8%
Q2 FY2024CQ2 2024Jun 30, 2024$27.10M+27.8%
Q1 FY2024CQ1 2024Mar 31, 2024$24.90M+10.7%
Q4 FY2023CQ4 2023Dec 31, 2023$21.00M-10.3%
Q3 FY2023CQ3 2023Sep 30, 2023$24.00M+17.1%
Q2 FY2023CQ2 2023Jun 30, 2023$21.20M+4.4%
Q1 FY2023CQ1 2023Mar 31, 2023$22.50M+6.1%
Q4 FY2022CQ4 2022Dec 31, 2022$23.40M+34.5%
Q3 FY2022CQ3 2022Sep 30, 2022$20.50M+4.1%
Q2 FY2022CQ2 2022Jun 30, 2022$20.30M+8.0%
Q1 FY2022CQ1 2022Mar 31, 2022$21.20M-0.5%
Q4 FY2020CQ2 2020Jun 30, 2020$17.40M-16.7%
Q3 FY2020CQ1 2020Mar 31, 2020$19.70M-8.4%
Q2 FY2020CQ4 2019Dec 31, 2019$18.80M-16.1%
Q1 FY2020CQ3 2019Sep 30, 2019$21.30M+0.9%
Q4 FY2019CQ2 2019Jun 30, 2019$20.90M+18.1%
Q3 FY2019CQ1 2019Mar 31, 2019$21.50M+16.2%
Q2 FY2019CQ4 2018Dec 31, 2018$22.40M+33.3%
Q1 FY2019CQ3 2018Sep 30, 2018$21.10M+18.5%
Q4 FY2018CQ2 2018Jun 30, 2018$17.70M-5.9%
Q3 FY2018CQ1 2018Mar 31, 2018$18.50M+5.1%
Q2 FY2018CQ4 2017Dec 31, 2017$16.80M-9.7%
Q1 FY2018CQ3 2017Sep 30, 2017$17.80M-8.2%
Q4 FY2017CQ2 2017Jun 30, 2017$18.80M-3.6%
Q3 FY2017CQ1 2017Mar 31, 2017$17.60M+2.3%
Q2 FY2017CQ4 2016Dec 31, 2016$18.60M+11.4%
Q1 FY2017CQ3 2016Sep 30, 2016$19.40M+12.8%
Q4 FY2016CQ2 2016Jun 30, 2016$19.50M+4.3%
Q3 FY2016CQ1 2016Mar 31, 2016$17.20M+3.0%
Q2 FY2016CQ4 2015Dec 31, 2015$16.70M–
Q1 FY2016CQ3 2015Sep 30, 2015$17.20M–
Q4 FY2015CQ2 2015Jun 30, 2015$18.70M–
Q3 FY2015CQ1 2015Mar 31, 2015$16.70M–

More Myriad Genetics figures

See a number that looks wrong?